A recent study published in JAMA Network Open suggests that GLP-1 receptor agonists, such as semaglutide (Ozempic) and tirzepatide (Mounjaro), may be associated with an increased risk of a rare eye disorder called non-arteritic anterior ischemic optic neuropathy (NAION). Researchers analyzed data from over 1 million individuals with type 2 diabetes who took these medications, as well as controls on non-GLP-1 diabetes drugs.
The study found that nearly twice the number of people taking GLP-1 drugs developed NAION within two years, compared to those taking other diabetes medications. However, this increase in risk was relatively small and still considered low. The researchers suggest that further research is needed to understand how these medications may affect eye health and who may be at higher risk.
It’s essential for patients and providers to be aware of the potential risks associated with GLP-1 receptor agonists, even if they are not high enough to counteract the benefits of these life-changing drugs. The study’s findings serve as a reminder that while these medications offer significant advantages, there is always more to learn about their effects on human health.
Source: https://www.medscape.com/viewarticle/does-this-side-effect-spell-doom-glp-1s-2025a1000l4n